Dr Reddy's Laboratories launches generic Concerta in US market

Anthony Fernandes
/ Categories: Trending, DSIJ News
Dr Reddy's Laboratories launches generic Concerta in US market

The shares of Dr Reddy’s Laboratories were trading up by 2 per cent on Thursday after the pharma major announced the launch of Methylphenidate Hydrochloride extended-release tablets USP, 18 mg, 27 mg, 36 mg, and 54 mg, a therapeutic equivalent generic version of Concerta in the US market. The drug is approved by United States Food & Drug Administration (USFDA).

Concerta brand and the generic market had US sales of approximately US$ 1.159 billion MAT for the most-recent twelve-month ending in June 2020, according to IQVIA Health.

Dr Reddy’s Methylphenidate Hydrochloride extended-release tablets, USP are available in the strengths of 18 mg, 27 mg, 36 mg, and 54 mg tablets in bottle count sizes of 100.

Dr Reddy’s Laboratories is an integrated pharmaceutical company, which operates through its three businesses, namely, pharmaceutical services & active ingredients, global generics, and proprietary products. The company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, and differentiated formulations.

On Thursday, the stock of Dr Reddy’s Laboratories closed at Rs 4,431.70 per share, higher by 1.76 per cent or Rs 76.45 per share on BSE, against a 0.24 per cent decline in the benchmark index. The 52-week high is recorded at Rs 4,754.30 and the 52-week low is Rs 2,497.60 on BSE.

Rate this article:
4.2
Comments are only visible to subscribers.

DSIJ MINDSHARE

Mkt Commentary 19-Jan, 2022

Quarterly Results 19-Jan, 2022

Mindshare 19-Jan, 2022

Mindshare 19-Jan, 2022

Mindshare 19-Jan, 2022

Knowledge

  • Back to top